INDV Stock: What Sublocade Growth Signals for 2026

Indivior is leaning on Sublocade as its primary growth engine, with the 2025 revenue reaching $1.2 billion, Sublocade contributing $856 million, up 13% year over year, and more than 500,000 patients prescribed since 2018. Sublocade held a 76% share of the U.S. long-acting injectable opioid use disorder segment in 2025. In Q1 2026, total net revenues were $317 million, with Sublocade net revenues up 32% to $232 million and dispense units up 20% year over year, supported by stronger commercial execution and a broader prescriber base. Payor coverage remains strong at 88% plus, and management notes improved price and mix. Indivior also discussed strategic shifts, including not pursuing INDV-6001 in Phase III and revising its Alar Pharmaceuticals license, while pursuing external development to strengthen the portfolio. The 2026 outlook hinges on continued Sublocade traction and a broader commercialization push.